Stressgen - Kurssprung erwartet - 500 Beiträge pro Seite

[blacksunday]

Heute um 15:30 Uhr gibt es sicherlich einen deutlichen Kursprung Richtung 15 Cad. $.

Habe gerade noch 300 Stressgen zu 6,90 Euro gekauft.


Wednesday July 26, 12:37 pm Eastern Time

Press Release

SOURCE: Toronto Stock Exchange; TSE Trading Halts/Resumptions

The Toronto Stock Exchange - Trading Halt -
StressGen Biotechnologies - SSB

TORONTO, July 26 /CNW/ - The Toronto Stock Exchange has issued the following trading halt:


Issuer Name: StressGen Biotechnologies
TSE Ticker Symbol: SSB
Time of Halt: 12:26
Reason for Halt: Pending News

[tork]

Hallo blacksunday,

gestern hat Toronto bei 9.75 geschlossen laut rse.com. Warum wurde dann Stressgen ausgesetzt ? Ist der Handel wieder aufgenommen worden ?

[Enno72]

Der Handel wurde um 2.30 pm Ortszeit aber wieder aufgenommen.
Vorbörslich sieht es aber nicht nach einem enormen Kurssprung aus.

[tork]

Hallo ENNO72,

vielen Dank für die Info. Auf welcher Seite siehst Du die vorbörslichen Kurse ? Kenne nur tse.com ! Danke !

Hallo Blacksunday,

woher Dein Optimismus auf Richtung 15 Euro ???

[Enno72]

Ich schaue nur bei "Yahoo Finance" und schaue mir das Bid/Ask
an. Und was ich da jetzt gerade sehe gefällt mir überhaupt nicht.

[blacksunday]

Stressgen erwacht wieder; kleine Schritte Richtung 15 Cad. $.
Heute ein Schlußkurs von 8,45 $, + 6,29 %.

[ErnieEarn]

hi Leute,

schön daß das Volumen wieder anzieht, gestern 160k in USA ist doch schon was !
Gruß und beste Kurse
EE

[inkas]

Dein Kurssprung ist da (auf 5.15 CAD, +11,96% 19.54 Uhr), aber nur in Canada hier geht keiner hin....
Schade. Inkas

[toller]

Stressgen`s HspE7 receives orphan drug status for recurrent respiratory papillomatosis
VICTORIA, BC, March 29 /CNW/ - Stressgen Biotechnologies Corporation (TSE: SSB - news) announced today that the United States Food and Drug Administration (FDA) has granted orphan drug status for HspE7, a novel immunotherapeutic, for the treatment of a human papillomavirus (HPV)-related disease called recurrent respiratory papillomatosis (RRP). The FDA grants orphan drug designations to provide economic incentives to stimulate the research, development and approval of products that treat rare diseases. Stressgen Biotechnologies is evaluating the potential of HspE7 as a broad based therapeutic for diseases caused by HPV. The Company currently has a number of clinical trials ongoing, including one Phase III trial and several Phase II trials. "The orphan designation will help us investigate the potential of HspE7, our immunotherapy for HPV, in addressing this important unmet medical need," said John R. Neefe, M.D., Vice President, Clinical Research and Regulatory Affairs for Stressgen Biotechnologies.
RRP is caused by HPV types six and eleven - the same types of HPV that cause genital warts. In a small subset of susceptible individuals, HPV causes tumor-like lesions to grow on the larynx and, in some cases, in the trachea and lungs. Left untreated, these tumors can cause suffocation and death. The incidence of RRP is spread evenly between children and adults. Lesions in RRP tend to recur, even after numerous and repeated surgical interventions. It is estimated that there are between 5,000 and 25,000 people in the United States who suffer from RRP.

"RRP can be a tragic disease, especially in children, and we believe that HspE7 offers hope in the treatment and management of this disease," said Daniel L. Korpolinski, President and Chief Executive Officer of Stressgen Biotechnologies. "We view the FDA`s decision as a significant milestone for the Company, and as an opportunity to further realize the potential for HspE7 as a cornerstone treatment for a wide variety of HPV infections."

Under the Orphan Drug Act (ODA), sponsors are encouraged to conduct open protocols allowing patients to be added to ongoing studies. Grant funding is available to defray costs of qualified clinical testing expenses incurred in connection with the development of orphan drug products. In addition, the ODA enables companies to apply for research funding, tax credits for certain research expenses and a waiver from the FDA`s application user fee.

HspE7, a recombinant fusion product created with Stressgen`s proprietary Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from Mycobacterium-bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from the HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on abnormal cells.

Stressgen Biotechnologies is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 in HPV-related diseases, the Company has also initiated research studies to evaluate its Hsp technology in the treatment of asthma, allergy and Hepatitis. Stressgen is an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology, which are used by scientists worldwide.

The foregoing press release contains statements that involve risks and uncertainties, including, without limitation, statements containing the words "believes", "may", and "will", and discussions of our on-going clinical trials and plans to develop and commercialize products. Such statements may constitute "forward-looking" statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. A number of factors could cause actual results, performance or achievements of the Company to be materially different from those implied by such statements. Such factors include, but are not limited to, those with respect the timing and success of planned or existing clinical trials, the timing of regulatory submissions and approvals, the ability of the Company to continue to develop its products (including HspE7), and the Company`s ability to maintain, protect and expand its intellectual property position, all as described in the Company`s Registration Statement on Form F-10 and other filings with the United States Securities and Exchange Commission.

[Mammon77]

hat jemand mal den genauen umrechnungskurs?? ich dachte eigentlich das sie bei 5,2Can$ hier so um die 4Euro stehen müssten?? nun ja, hauptsache es geht nach oben!!

MfG

[inkas]

hier: http://quote.yahoo.com/m3

[Andrax]

jetzt sinds ja nur noch 38% bis zu meinem kk

Stressgen presents new data indicating the majority of anal dysplasia patients improve with HspE7

07:59 GMT-04:00 Tuesday, April 24, 2001



Data Confirm Earlier Findings: 73% of Patients Downgrade from High Grade

to Low Grade Dysplasia

BETHESDA, MD, April 24 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB) announced today that additional preliminary Phase II data confirm previously reported activity of HspE7, a novel immunotherapeutic, for the treatment of a precancerous condition caused by human papillomavirus (HPV) called anal dysplasia (AIN). At the 5th International AIDS Malignancy conference, Joel M. Palefsky, M.D., one of the foremost international experts in AIN, reported updated results of an open-label Phase II trial in high grade anal dysplasia. Data from the first 22 consecutive patients were reported at the primary six-month evaluation point where 16 of 22 patients (73%) downgraded to low grade dysplasia. These data are consistent with the initial reports of this ongoing trial.

"These data continue to support Stressgen`s belief that HspE7 could become an important therapeutic option for HPV-related diseases such as anal dysplasia. Many patients now require some form of surgery - a potentially painful and debilitating procedure. HspE7 could potentially eliminate the need for surgery," said John R. Neefe, M.D., Vice President, Clinical Research and Regulatory Affairs of Stressgen. To date, no serious adverse events related to HspE7 treatment have been observed in the patients reported. Stressgen plans to analyze the final data from the completed Phase II AIN trial during the third quarter of 2001. The data will then be submitted for initial public presentation at an appropriate scientific forum. Stressgen`s phase III trial in anal dysplasia is actively enrolling patients and is progressing according to schedule.

"At the 5th International AIDS Malignancy Conference, it has become increasingly apparent that anal dysplasia is an important public health problem, especially among HIV-infected gay men," said Dr. Palefsky, Director of the General Clinical Research Center and Professor of the Departments of Laboratory Medicine and Stomatology at the University of California, San Francisco. "Anal dysplasia is more common than anyone had previously known, and it can have serious medical implications if left untreated. We now recognize that anal dysplasia affects many men with HIV infection. Worse, the incidence of anal cancer, which may be a consequence of anal dysplasia, appears to be increasing rapidly in this group. New approaches to the treatment of anal dysplasia are badly needed."

The Company is evaluating the potential of HspE7 as a broad based therapeutic for diseases caused by human papillomavirus (HPV). The Company currently has a number of clinical trials ongoing, including one Phase III trial, and several Phase II trials, and will soon initiate a clinical trial to evaluate HspE7 for the treatment of a serious HPV-related disease, recurrent respiratory papillomatosis (RRP), for which the FDA recently granted orphan drug status. RRP is caused by the same HPV types that cause genital warts.

HspE7, a recombinant fusion product created with Stressgen`s proprietary Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from Mycobacterium bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system attack on infected cells.


Conference Call

---------------

Stressgen will hold its First Quarter 2001 financial conference call on May 3, 2001 at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). The call in number to access the call is 800/326-6186 in North America. A replay of this call will be available from May 3 at 3:00 Pacific Time through May 10, 2001. The playback number is: 800/558-5253, reservation number 18670407. To access information about the call, please log on to our website, www.stressgen.com

[gondor]

@all

kann mir jemand hier sagen, wieviel prozent der medikamente, die in der gleichen phase wie das vorher erwähnte sind, eigentlich noch scheitern?

vielen dank

gondor

[micha200]

bist wohl im falschen Board?
Stressgens Medikament haben bis jetzt
alle angeschlagen.

[nochnichtpleite]

@micha
"Angeschlagen", die Frage ist aber bei wem:

Den Versuchspatienten oder nur bei Tieren im Labor ?

[micha200]

Wer Biotechnologieaktien kauft, sollte sich in den Grund-
legenden Dingen schon auskennen.
Hier für die Unwissenden:
Vorklinische Phase: Versuche an Tieren (etwa 1 Jahr)
Phase I: Test an gesunden Personen (6-12 Monate)
Phase II: An Kranken Personen (1-2 Jahre)
Phase III: Test an mehreen! hundert Patienten
(1-2 Jahre)
Alles klar jetzt?

.Und wenn man sich jetzt noch die
Mühe macht, bei Streßgens Homepage reinzuschauen,und zur Not
ein Wörterbuch zur Hand nimmt,dann stellt man hier auch nicht solche Behauptungen auf.
Ich hoffe eigentlich, das ich hier wichtige infos finden kann.
Nachfolgend ist zu lesen, das die Daten in den klinischen PhasenII und III positive Ergebnisse haben,das heißt das die Prozentuale Wirksamkeit in der Vorgeschriebenen Range liegt.
Welche Medikamente das betrifft,welches Marktvolumen sie haben,poste ich nicht mehr,da schon mehrfach getan.
Gruß Michael

Stressgen Presents New Data Indicating The Majority Of Anal Dysplasia Patients Improve With HspE7
Data Confirm Earlier Findings: 73% of Patients Downgrade from High Grade to Low Grade Dysplasia
Bethesda, Maryland

Stressgen Biotechnologies Corporation (TSE:SSB) announced today that additional preliminary Phase II data confirm previously reported activity of HspE7, a novel immunotherapeutic, for the treatment of a precancerous condition caused by human papillomavirus (HPV) called anal dysplasia (AIN). At the 5th International AIDS Malignancy conference, Joel M. Palefsky, M.D., one of the foremost international experts in AIN, reported updated results of an open-label Phase II trial in high grade anal dysplasia. Data from the first 22 consecutive patients were reported at the primary six-month evaluation point where 16 of 22 patients (73%) downgraded to low grade dysplasia. These data are consistent with the initial reports of this ongoing trial.

"These data continue to support Stressgen`s belief that HspE7 could become an important therapeutic option for HPV-related diseases such as anal dysplasia. Many patients now require some form of surgery ­ a potentially painful and debilitating procedure. HspE7 could potentially eliminate the need for surgery," said John R. Neefe, M.D., Vice President, Clinical Research and Regulatory Affairs of Stressgen. To date, no serious adverse events related to HspE7 treatment have been observed in the patients reported. Stressgen plans to analyze the final data from the completed Phase II AIN trial during the third quarter of 2001. The data will then be submitted for initial public presentation at an appropriate scientific forum. Stressgen¹s phase III trial in anal dysplasia is actively enrolling patients and is progressing according to schedule.

[gondor]

@micha200

du hast natürlich recht, aber gier macht ja bekanntlich blind. und jetzt sitze ich auf den aktien und weiß so recht eigentlich gar nicht bescheid.

dank dir kann ich jetzt stressgen aber wenigstens ein wenig einordnen.

nochmal vielen dank

gondor

[Mammon77]

ist ja ganz schön ruhig geworden um stressgen??!! die kurse sind laut umrechnung auch nicht grad das was sie normal wert sein müssten!! na ja, langsam aber sicher wird es aufwärtsgehen!!! gibt es eigentlich sooooo wenig news, es schreibt ja niemand etwas?!!

MfG

[inkas]

okay schreib ich eben mal was...
@ mammon77 genau das ist auch mein Problem mit dieser Aktie: wenig news, Kurs entspricht nicht der Umrechnung. Allerdings liegt meine Hoffnung in dem allg. Biotech-Aufschwung. Nach und nach werden die Leute jetzt versuchen noch in billige Biotech-Aktien zu kommen, bevor auch die wieder anziehen. Jedenfalls hat heut mal einer in FMN gekauft.....
let`s wait and see... Inkas

[micha200]

man hat sich natürlich immer noch die Kurskapriolen von 2000 im Hinterkopf.Meine Stressgen sind auch noch 30 % im
Minus.bin selber schuld,hatte keine stopp.marken.ICh glaube die Nasdaq ist über das schlimmste weg.Abwärtstrend verlassen.Stressgen hat sich von seinem Tief immerhin schon 40% erholt.Parrallel zur Nasdaq.
Mehr ist nicht zu erwarten.Man braucht Geduld.Mit Stressgen handeln wir momentan nur Phantasie.Wenn sich das ändert,dann wird mit SIcherheit mehr bewegung reinkommen.
Gruß an alle (ge)stressgen

[inkas]

mal eine neue Info und garnicht mal so schlecht wie ich finde. Kam allerdings erst nach Boersenschluss raus:

Stressgen conference call notification
Thursday, June 7, 2001 at 9:00 a.m. ET; 6:00 a.m. PT
SAN DIEGO, CA, June 1 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced today that it will hold a conference call on Thursday, June 7 to discuss Dr. Stephen Goldstone`s presentation of genital warts clinical data for HspE7 at the American Society of Colon and Rectal Surgeons (ASCRS) Annual Meeting. The ASCRS 2001 meeting will be held June 2-7 in San Diego. Dr. Goldstone`s presentation is scheduled between 10:00 a.m. and 1:00 p.m. on Wednesday, June 6. Abstracts and conference proceedings for the ASCRS meeting will be available to conference registrants on June 2 through June 7.


hoert sich doch gut an - oder?
die werden doch nicht eine conference einberufen, wenn es keine super Daten von Goldstone waeren.....
tgif Inkas

[inkas]

geht wohl doch keiner hin...........

[inkas]

na bitte:
Preliminary clinical data demonstrate robust activity for HspE7 in genital warts
New Data Presented at the American Society of Colon and Rectal Surgeons Meeting Confirm Broad Spectrum Activity of HspE7 for the Treatment of HPV-related Diseases
SAN DIEGO, CA, June 6 /CNW/ - Stressgen Biotechnologies Corporation (TSE:SSB - news) announced that new data presented today at the American Society of Colon and Rectal Surgeons Annual Meeting, June 2-7, 2001 suggest that HspE7 may be active in treating genital warts caused by the human papillomavirus (HPV). The clinical observations reported retrospectively were made during Stressgen`s Phase II open-label trial in anal dysplasia (AIN) where 14 of the first 22 patients enrolled at one study center also had genital warts. At six months, 13 of 14 patients (93%) responded to HspE7. Of the total patients reported, 10 of 14 (71%) had warts reduced in size 70-95% and 3 of 14 (21%) had complete resolution. These responses are not HPV-16 specific, indicating that HspE7 activity crosses multiple HPV types.
"These data suggest that HspE7 is broadly active in anogenital warts, enhancing its potential as an important new therapeutic for HPV-related diseases," said John R. Neefe, M.D., Vice President of Clinical and Regulatory Affairs of Stressgen. Encouraged by these observations, Stressgen has opened a randomized double-blind, placebo-controlled Phase II trial designed to examine the activity of HspE7 in genital warts. Enrollment in this trial is complete and data from this trial should be available for analysis in the fourth quarter of 2001.

Genital warts are caused by certain types of HPV, one of the most common sexually transmitted diseases in the world infecting 24 million people in the U.S. alone. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S., of which over one million represent new cases of genital warts. Existing treatments for genital warts use ablative methods, involving surgery or the application of topical agents to the surface of each wart. The majority of patients, however, will experience recurrent episodes within three to six months. In addition to genital warts, HPV is responsible for a variety of precancerous and cancerous conditions. HPV is also responsible for a serious HPV-related disease known as recurrent respiratory papillomatosis (RRP), which is caused by the same types that cause genital warts.

"The medical community is becoming increasingly aware of the seriousness of HPV-related diseases such as genital warts and precancerous lesions. Treatment recommendations are evolving, however, many patients require some form of surgical ablative treatment. With the high recurrence of genital warts, these procedures are painful and can leave the patient debilitated over many weeks to months of repeated treatments. New therapies are badly needed, and the possibility of an immune-based therapy is very exciting because it has the potential to avoid surgery, improve quality of life and hopefully decrease recurrence. These HspE7 clinical data appear to be very promising. I look forward to further clinical results," said Stephen E. Goldstone, M.D. Dr. Goldstone, a leading AIN specialist, is a Fellow of the American College of Surgeons. He is on the teaching faculty of The Mount Sinai School of Medicine and has a surgical practice in New York City.

Results presented today by Dr. Goldstone were in the form of a retrospective chart review from patients evaluated by physical examination at baseline and six months as to the percentage reduction in wart size. The reduction in wart size in the 13 responders markedly diminished the procedure that would be necessary for complete ablation. Of the 14 patients with genital warts, one patient did not respond to HspE7. In the majority, the warts improved substantially but did not disappear totally within six months. No serious adverse events in the patients reported were related to HspE7.

HspE7, a recombinant fusion product created with Stressgen`s proprietary Hsp fusion technology, is composed of heat shock protein 65 (Hsp65) from Mycobacterium bovis BCG and the protein E7. As a member of the family of stress proteins, Hsp65 is known to elicit a powerful immune response. The E7 protein is derived from HPV and is involved in the malignant transformation of epithelial cells. E7 is a tumor-specific antigen and represents a precise target for the immune system to attack abnormal cells.
und was macht der Kurs????
Gruss Inkas

[Mammon77]

Juchu, endlich wird es aufwärts gehen!! ich bin seit 7euro dabei und kann ja hoffen das wir diese kurse bald wieder sehen werden!! da ich ja nicht pushen möchte, HOFFE ich einfach nur mal auf nen 2stelligen kurs!!!

MfG

[inkas]

okay, zwar von gestern, aber wieder eine INFO:

Related Quotes

SSB.TO
6.68
-0.10

delayed 20 mins - disclaimer



Wednesday June 6, 3:40 pm Eastern Time
Stressgen stock soars on wart drug`s potential
TORONTO, June 6 (Reuters) - Shares of Stressgen Biotechnologies (Toronto:SSB.TO - news) soared 17 percent on Wednesday after the company said its lead drug has shown early success in treating genital warts, a sexually transmitted disease with scant treatment options and no known cure.
ADVERTISEMENT



Victoria, British Columbia-based Stressgen said its HspE7 drug, which uses stress proteins to stimulate the immune system, reduced the size of genital warts in the majority of patients tested.

The findings were presented at the annual meeting of the American Society of Colon and Rectal Surgeons in San Diego, California, on Wednesday.

The results were uncovered while Stressgen was testing HspE7 in a phase 2 study for the treatment of anal dysplasia --or the growth of abnormal cells in the anus -- in a sampling of 22 patients, 14 of which also had genital warts.

After six months, 13 of the 14 patients responded to HspE7, with the warts in 10 of those patients shrinking 70 percent to 95 percent, and warts in the remaining three patients disappearing altogether.

Shares of Stressgen rose as much as 17 percent, or C$1.05, to C$6.92 on the Toronto Stock Exchange on Wednesday, where they have traded in a 52-week range of C$10.20 to C$4.30. The shares have gained 27 percent in the past year, outperforming the TSE biotech index, which is flat over the same period.

``New therapies are badly needed, and the possibility of an immune-based therapy is very exciting because it has the potential to avoid surgery, improve quality of life and hopefully decrease recurrence,`` said Dr. Stephen Goldstone, the lead researcher on the study, and a specialist in the field.

Genital warts are estimated to affect 24 million people in the United States with a million new cases each year. Existing treatments involve surgery or creams applied to the skin, although recurrence is common within six months of treatment.

Stressgen said it has completed enrollment for a phase 2 trial on the efficacy of HspE7 for genital warts, and expects full data to be available in the fourth quarter of 2001.

[inkas]

ich glaube, mehr als die 5,05 von heute ist fuer eine Weile
(1 Woche?....)erst mal nicht drin. Ganz klar, dass es heute in CAN Gewinnmitnahmen geben wird. Hoffe nur, die Nachrichtenlage bessert sich, damit fuer mehr Leute die Aktie wieder interessant wird.
tgif Inkas

[Marceljim]

das wars dann wohl fuers erste mit der 5,... da hat einer wohl maechtig gewinne mitgenommen. nun denn, mal sehen wies weitergeht.

[inkas]

momentan steigt die Aktie in CAN knapp 3% (2,97 um genau zu sein) und das bei dem Umfeld (Biotech-Indices ^BTK und ^NBI mit -4,3 bzw. -3.9 klar im neg. Territorium), laesst mich wieder hoffen............
gruss an alle Gestressten Inkas

[XX10]

STRESSGEN BIOTECHNOLOGIES CORP ("SSB-T") - Conference Call Notification ("SGBXF-0")
Stressgen Biotechnologies Corporation announced that it will hold a conference call on Thursday, August 2, 2001 to discuss its second quarter 2001 financial results and provide an update on the progress of the Company.

About Conference Call

Stressgen`s conference call will be held on August 2, 2001 at 4:00 p.m. Eastern Time (1:00 p.m. Pacific Time). The dial in number to access the call is: 888-243-1119 in North America. A replay of this call will be available from August 2 at 3:00 p.m. Pacific Time through August 8, 2001. The playback number is: 800-558-5253, reservation No. 19408921. The Company will retain information about accessing the call on its website at www.stressgen.com through the playback period.

About Stressgen

Stressgen is a public biopharmaceutical company focused on the development and commercialization of innovative stress protein-based immunotherapeutics. The Company is developing a broad range of products for the treatment of viral infections and related cancers. In addition to targeting HspE7 for HPV-related diseases, the Company also has a program to evaluate stress protein fusions in hepatitis B and several other indications. Stressgen is also an internationally recognized supplier of research products for the study of cellular stress, apoptosis, oxidative stress and neurobiology used by scientists worldwide.

HspE7 is a novel immunotherapeutic for the treatment of diseases caused by the human papillomavirus ("HPV"), one of the most common sexually transmitted diseases, estimated to infect approximately 30 to 50 percent of the sexually active population. There are 5.5 million new cases of genital HPV infection diagnosed per year in the U.S. alone, of which over 1 million represent cases of genital warts. In addition to warts, genital HPV infection can cause cervical cancer and a variety of precancerous conditions, including anal and cervical dysplasia.

This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the development and commercialization of therapeutics for viral infections, cancers and other diseases. Factors that may cause the ultimate results of our performance to be materially different from those implied by such forward-looking statements include risks that the products are not demonstrated to be safe or effective for their intended use, that the company will not obtain approval to market its products, and that there will be delays in proceeding from research to commercialization. These factors and others are more fully discussed in our filings with the U.S. Securities and Exchange Commission and Canadian regulatory authorities. TEL: [phone] Donna Slade, Director, Investor Relations FAX: [phone] EMAIL: [e-mail] TEL: [phone] Jennifer Matterson, Communications Coordinator FAX: [phone] EMAIL: [e-mail]

[boriz]

tja, ich weiss zwar keine einzelheiten, aber dieser conference call scheint ja recht negativ gewesen zu sein, oder warum -16% ???
bORiZ

[boriz]

http://www.stressgen.com/news/recent.pdf

hier ist der grund